Top Stories https://www.benzinga.com/views/taxonomy/term/138079 en What To Expect From Nvidia's Q2 Earnings https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12202014/what-to-expect-from-nvidias-q2-earnings <p><strong>NVIDIA Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) is scheduled to report its second-quarter results after Thursday&#39;s close. Analysts, on average, expect EPS of $1.66 on revenue of $3.1 billion.</p> <h3>The Analysts</h3> <p>BMO Capital Markets&#39; Ambrish Srivastava maintains a Market Perform rating on <a href="https://www.benzinga.com/stock/nvda">Nvidia</a> with an unchanged $225 price target. Elsewhere, Stacey Gilbert, head of derivative trading at Susquehanna, talked options play on CNBC.</p> <h3>The Thesis</h3> <p>Srivastava is modeling Nvidia to show the following:</p> <ul> <li>Revenue down 3 percent from the prior quarter to $3.1 billion.</li> <li>GAAP gross margin of 63.3 percent.</li> <li>GAAP EPS of $1.65.</li> <li>Inventory of 77 days.</li> <li>Cryptocurrency-related concerns will take a backseat towards other favorable drivers of the business.</li> </ul> <h3>Gilbert: Ordinary ...</h3><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12202014/what-to-expect-from-nvidias-q2-earnings alt=What To Expect From Nvidia&#039;s Q2 Earnings>Full story available on Benzinga.com</a></p> Ambrish Srivastava Analyst Color BMO Capital Markets CNBC Cryptocurrency NVDA Stacey Gilbert Trading Nation Previews Options Top Stories Markets Analyst Ratings Media Trading Ideas NVDA US67066G1040 Analyst Color Cryptocurrency Previews Options Top Stories Markets Analyst Ratings Media Trading Ideas Benzinga Tue, 14 Aug 2018 19:26:24 +0000 Jayson Derrick 12202014 at https://www.benzinga.com Sports Drink Wars: Coca-Cola Acquires BodyArmor Stake In Challenge To Gatorade https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12202323/sports-drink-wars-coca-cola-acquires-bodyarmor-stake-in <p><strong>The Coca-Cola Co</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)&#39;s&nbsp;Powerade may never been able to match up with <strong>PepsiCo, Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pep#NASDAQ">PEP</a>)&#39;s Gatorade, but Coca-Cola has&nbsp;a new plan to win the sports drink wars.</p> <h3>What Happened?</h3> <p>Coca-Cola&nbsp;announced Tuesday it has acquired a <a href="https://www.benzinga.com/pressreleases/18/08/b12197477/the-coca-cola-company-and-bodyarmor-announce-new-strategic-relationshi">minority stake in the fast-growing sports drink company BodyArmor</a>, with a path to ownership under defined terms. The terms of the deal were not disclosed.</p> <h3>Why It Matters?</h3> <p>Founded in 2011 by VitaminWater/Smartwater founder Mike Repole, BodyArmor is a fast-growing drink in the&nbsp;category and is expected to hit $400 million in revenue in 2018 &mdash; up from $235 million in 2017.</p> <p>The brand has high-profile minority owners including Kobe Bryant, who has ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12202323/sports-drink-wars-coca-cola-acquires-bodyarmor-stake-in alt=Sports Drink Wars: Coca-Cola Acquires BodyArmor Stake In Challenge To Gatorade>Full story available on Benzinga.com</a></p> Analyst Color Beverage Digest BodyArmour Bonnie Herzog Gatorade KDP KO Kobe Brant Mike Repole Mike Trout News PEP Powerade Wells Fargo M&A Top Stories Analyst Ratings KO US1912161007 PEP US7134481081 KDP News Analyst Color M&A Top Stories Analyst Ratings Benzinga Tue, 14 Aug 2018 19:01:35 +0000 Brett Hershman 12202323 at https://www.benzinga.com Analyst Still Optimistic On Casino Stocks, Upgrades Boyd Gaming https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12201623/analyst-still-optimistic-on-casino-stocks-upgrades-boyd <p>Casino stocks have taken a beating in recent weeks, and one Wall Street analyst says it&rsquo;s time for investors to step in and buy the dip in a handful of top stocks.</p> <h3>The Analyst</h3> <p>Jefferies analyst David Katz updated his ratings and price targets for the following gaming stocks:</p> <ul> <li>Upgraded <strong>Boyd Gaming Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/byd#NYSE">BYD</a>) from Hold to Buy and reiterated a $42 price target.</li> <li>Downgraded <strong>Wynn Resorts, Limited</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wynn#NASDAQ">WYNN</a>) from Buy to Hold and lowered his price target from $229 to $170.</li> <li>Reiterated a Buy rating and $36 price target for <strong>MGM Resorts International</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mgm#NYSE">MGM</a>).</li> <li>Reiterated a Buy rating and $40 price target for <strong>Penn National Gaming, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/penn#NASDAQ">PENN</a>).</li> <li>Reiterated a Buy ...</li></ul><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12201623/analyst-still-optimistic-on-casino-stocks-upgrades-boyd alt=Analyst Still Optimistic On Casino Stocks, Upgrades Boyd Gaming>Full story available on Benzinga.com</a></p> Analyst Color BYD casinos David Katz GDEN Jefferies Las Vegas Macau MGM PENN WYNN Upgrades Downgrades Price Target Top Stories Analyst Ratings PENN US7075691094 WYNN US9831341071 BYD US1033041013 MGM US5529531015 GDEN Analyst Color Upgrades Downgrades Price Target Top Stories Analyst Ratings Benzinga Tue, 14 Aug 2018 17:50:09 +0000 Wayne Duggan 12201623 at https://www.benzinga.com The Most Searched Questions About Jeff Bezos https://www.benzinga.com/general/education/18/08/12157237/the-most-searched-questions-about-jeff-bezos <p><strong>Alphabet, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>) (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) subsidiary Google is the gold standard of internet search and the primary destination for Americans with questions about just about anything. <strong>Amazon.com, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) CEO Jeff Bezos is the world&rsquo;s richest man, so it&rsquo;s understandable that Google users would have plenty of questions about Bezos.</p> <p>Benzinga recently used the Google autocomplete feature to get a feel for exactly what people are asking about Bezos.</p> <h3>Biggest Bezos Questions</h3> <p>Understandably, most of the results have to do with his $150 billion fortune.</p> <p>For example, by typing &ldquo;What does Jeff Bezos&hellip;&rdquo; Google makes the following suggestions:</p> <ul> <li>&ldquo;...do?&rdquo;</li> <li>&ldquo;...drive?&rdquo;</li> <li>&ldquo;...make?&rdquo;</li> <li>&ldquo;...earn a day?&rdquo;</li> <li>&ldquo;...do now?&rdquo;</li> </ul> <p>It seems as though people are curious not only about how much money ...</p><p><a href=https://www.benzinga.com/general/education/18/08/12157237/the-most-searched-questions-about-jeff-bezos alt=The Most Searched Questions About Jeff Bezos>Full story available on Benzinga.com</a></p> AAPL AMZN Blue Origin GOOG GOOGL Google Jeff Bezos Washington Post Education Crowdsourcing Top Stories General AAPL US0378331005 AMZN US0231351067 GOOG US38259P7069 GOOGL US38259P5089 Education Crowdsourcing Top Stories General Benzinga Tue, 14 Aug 2018 17:18:36 +0000 Wayne Duggan 12157237 at https://www.benzinga.com What's Next For The Payment Space? https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12201252/whats-next-for-the-payment-space <p>Nineteen out of 24 payments and payment processor stocks under JPMorgan&#39;s coverage are outperforming the S&amp;P 500 index. Despite strong outperformance, the group remains attractive.</p> <h3>The Analyst</h3> <p>JPMorgan&#39;s Tien-tsin Huang made the following rating changes:</p> <ul> <li><strong>Alliance Data Systems Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ads#NYSE">ADS</a>) upgraded from Neutral to Overweight, price target lifted from $270 to $281.</li> <li><strong>Fiserv Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fisv#NASDAQ">FISV</a>) downgraded from Neutral to Underweight, price target lifted from $77 to $82.</li> <li><strong>Paychex, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payx#NASDAQ">PAYX</a>) downgraded from Neutral to Underweight, price target lifted from $67 to $76.</li> </ul> <h3>The Thesis</h3> <p>Payments and <a href="https://www.digitaltransactions.net/strong-profit-predictions-propel-payment-processor-stocks-in-2018s-first-half/">payment processor stocks</a> are up 26 percent since the start of 2018 on a market cap-weighted basis while the S&amp;P 500 index is up just 6 percent over the same time period, Huang said in a note. While there are some notable standouts in the group, including <strong>Square Inc</strong> ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12201252/whats-next-for-the-payment-space alt=What&#039;s Next For The Payment Space?>Full story available on Benzinga.com</a></p> ADS Analyst Color FISV JPMorgan Payment Processors payments PAYX SQ Tien Tsin Huang Upgrades Downgrades Price Target Top Stories Analyst Ratings Trading Ideas FISV US3377381088 PAYX US7043261079 ADS US0185811082 SQ Analyst Color Upgrades Downgrades Price Target Top Stories Analyst Ratings Trading Ideas Benzinga Tue, 14 Aug 2018 17:09:21 +0000 Jayson Derrick 12201252 at https://www.benzinga.com This Day In Market History: US Social Security Act Is Signed https://www.benzinga.com/general/education/18/08/12200057/this-day-in-market-history-us-social-security-act-is-signed <p><em>Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date.</em></p> <h3>What Happened?</h3> <p>On this day 83 years ago, the U.S. Social Security Act was signed into law.</p> <h3>Where The Market Was</h3> <p>The Dow Jones Industrial Average closed at 128.27 and the S&amp;P 500 traded at 11.37. Today, the Dow is trading at 25,187.79 and the S&amp;P 500 is trading at 2,821.93.</p> <h3>What Else Was Going On In The World?</h3> <p>In 1935, the construction of the Hoover Dam was completed. Sir Malcolm Campbell breaks the world land speed ...</p><p><a href=https://www.benzinga.com/general/education/18/08/12200057/this-day-in-market-history-us-social-security-act-is-signed alt=This Day In Market History: US Social Security Act Is Signed>Full story available on Benzinga.com</a></p> Franklin Roosevelt Ida May Fuller Social Security this day in market history Education Top Stories General Education Top Stories General Benzinga Tue, 14 Aug 2018 16:58:46 +0000 Wayne Duggan 12200057 at https://www.benzinga.com Investment Firm Launches Cannabis REIT, Aims To Solve Capital Dilemma https://www.benzinga.com/markets/cannabis/18/08/12200579/investment-firm-launches-cannabis-reit-aims-to-solve-capital-dilemma <p>The Inception Companies, the private investment firm behind <strong>Medmen Enterprises Inc</strong> (CNSX: MMEN) (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) and several other cannabis ventures, announced the <a href="http://www.inceptionreit.com/">launch of the Inception REIT</a> (I-REIT) to provide the cannabis industry with real estate debt and equity capital solutions.</p> <p>REITs, or real estate investment trusts, are companies that own or finance income-producing real estate.</p> <h3>What Happened</h3> <p>I-REIT offers medicinal and adult-use cannabis businesses senior debt originations, capital improvement financings and sale-leasebacks, essentially providing access to capital and enabling redeployment into business activities without diluting equity.</p> <p>Real estate is the &quot;lifeblood&quot; of the cannabis sector, and a key barrier for scaling brands and operating businesses, I-REIT CEO Richard Acosta told Benzinga.</p> <p>&quot;Due to current federal cannabis laws, many operators have acquired their real estate assets with cash and have significant capital locked up in those investments. We see this as a huge opportunity, not just to unlock these funds for growing their core businesses ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/08/12200579/investment-firm-launches-cannabis-reit-aims-to-solve-capital-dilemma alt=Investment Firm Launches Cannabis REIT, Aims To Solve Capital Dilemma>Full story available on Benzinga.com</a></p> Cannabis I-REIT IIPR Inception REIT MMNFF News REIT Richard Acosta The Inception Companies Top Stories Exclusives Markets Interview Real Estate IIPR MMNFF News Cannabis REIT Top Stories Exclusives Markets Interview Real Estate Benzinga Tue, 14 Aug 2018 15:42:42 +0000 Elizabeth Balboa 12200579 at https://www.benzinga.com Musk Name-Drops Advisors, Tesla Forms Committee To Evaluate Potential Go-Private Deal https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12200853/musk-name-drops-advisors-tesla-forms-committee-to-evalu <p><strong>Tesla Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk revealed Monday he is working with two major banks to take Tesla private, and Tesla announced it has created a formal committee to look into whether going private at $420 per share is in the best interest of Tesla stockholders.&nbsp;</p> <h3>What Happened?</h3> <p>Elon Musk<a href="https://www.cnbc.com/2018/08/14/musk-working-with-goldman-sachs-silver-lake-on-taking-tesla-private.html">&nbsp;tweeted</a> that he is working with investment bank <strong>Goldman Sachs Group Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>) and private equity company Silver Lake on constructing a deal to take Tesla private. Musk also said he has also hired Wachtell, Lipton, Rosen &amp; Katz and Munger, Tolles &amp; Olson as legal advisors.</p> <p>In a <a href="https://www.benzinga.com/pressreleases/18/08/g12199026/tesla-announces-formation-of-special-committee-to-evaluate-potential-g">separate announcement</a>, Tesla said its board has formed a committee of three independent directors to evaluate Musk&rsquo;s proposal on behalf of Tesla investors. In a press release, Tesla said it &ldquo;has not yet received a formal proposal from Mr. Musk regarding ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12200853/musk-name-drops-advisors-tesla-forms-committee-to-evalu alt=Musk Name-Drops Advisors, Tesla Forms Committee To Evaluate Potential Go-Private Deal>Full story available on Benzinga.com</a></p> Analyst Color Barclays Brian Johnson Elon Musk GS News TSLA Top Stories Analyst Ratings GS US38141G1040 TSLA US88160R1014 News Analyst Color Top Stories Analyst Ratings Benzinga Tue, 14 Aug 2018 15:00:04 +0000 Wayne Duggan 12200853 at https://www.benzinga.com Heavy Metal: Goldman Downgrades Kaiser Aluminum, Upgrades Commercial Metals https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12200482/heavy-metal-goldman-downgrades-kaiser-aluminum-upgrades <p>Goldman Sachs zeroed in on the metals and mining space this week after companies in the sector reported quarterly earnings.&nbsp;</p> <h3>The Analyst</h3> <p>Analyst <a href="https://www.tipranks.com/analysts/matthew-korn">Matthew Korn</a> downgraded&nbsp;<strong>Kaiser Aluminum Corp. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kalu#NASDAQ">KALU</a>) from <a href="http://https://www.benzinga.com/analyst-ratings/upgrades/18/08/12199633/benzingas-top-upgrades-downgrades-for-august-14-2018">Neutral to Sell</a> and reduced the 12-month price target from $105 to $101.</p> <p>The analyst upgraded <strong> Commercial Metals Company </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmc#NYSE">CMC</a>) from Sell to Neutral and maintained a 12-month price target of $24.</p> <h3>Anticipated EBITDA Improvement Inadequate To Support Multiple</h3> <p>After flattish performance over a three-year period, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/07/12024740/2-aluminum-stocks-to-buy-according-to-jefferies"> Kaiser </a> is poised to post strong EBITDA growth of 11 percent into 2019, supported by a moderation in aluminium costs, Korn said in a Monday note. (See the analyst&#39;s track record <a href="https://www.tipranks.com/analysts/matthew-korn">here</a>.)&nbsp;</p> <p>Kaiser&#39;s EV/EBITDA multiple has expanded to 8.9 times Goldman&#39;s 2019 forecast, notably above its five-year average ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12200482/heavy-metal-goldman-downgrades-kaiser-aluminum-upgrades alt=Heavy Metal: Goldman Downgrades Kaiser Aluminum, Upgrades Commercial Metals>Full story available on Benzinga.com</a></p> Analyst Color CMC CSTM Goldman Sachs KALU Matthew Korn Upgrades Downgrades Price Target Commodities Top Stories Markets Analyst Ratings KALU US4830077040 CMC US2017231034 CSTM Analyst Color Upgrades Downgrades Price Target Commodities Top Stories Markets Analyst Ratings Benzinga Tue, 14 Aug 2018 14:48:18 +0000 Shanthi Rexaline 12200482 at https://www.benzinga.com Switch's Guidance Shortfall Prompts JPMorgan Downgrade https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12199860/switchs-guidance-shortfall-prompts-jpmorgan-downgrade <p>Data center designer and technology infrastructure company <strong>Switch Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/swch#NYSE">SWCH</a>)&#39;s second-quarter earnings report and disappointing guidance prompted JPMorgan to drop its bullish stance.&nbsp;</p> <h3>The Analyst</h3> <p>JPMorgan&#39;s <a href="https://www.tipranks.com/analysts/richard-choe">Richard Choe</a> downgraded <a href="https://www.benzinga.com/stock/swch">Switch</a>&nbsp;from Overweight to Neutral with a price target lowered from $17 to $13.</p> <h3>The Thesis</h3> <p>Switch <a href="https://www.benzinga.com/pressreleases/18/08/r12195235/switch-announces-second-quarter-2018-financial-results">reported Monday afternoon</a>&nbsp;with an in-line earnings report but lowered its 2018 guidance, Choe said in the downgrade note. (See the analyst&#39;s track record <a href="https://www.tipranks.com/analysts/richard-choe">here</a>.)</p> <p>The company&#39;s sales forecast revision implies mostly flat revenue and margin performance from a year ago &mdash; which is disappointing, as Switch was expected to show a revenue ramp and margin ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12199860/switchs-guidance-shortfall-prompts-jpmorgan-downgrade alt=Switch&#039;s Guidance Shortfall Prompts JPMorgan Downgrade>Full story available on Benzinga.com</a></p> Analyst Color Data Center Earnings JPMorgan News Richard Choe SWCH Downgrades Price Target Top Stories Analyst Ratings SWCH News Analyst Color Earnings Downgrades Price Target Top Stories Analyst Ratings Benzinga Tue, 14 Aug 2018 14:14:53 +0000 Jayson Derrick 12199860 at https://www.benzinga.com The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut https://www.benzinga.com/general/biotech/18/08/12197141/the-daily-biotech-pulse-cesca-acer-therapeutics-rally-on-earnings-ari <p>Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.</p> <h3>Scaling the Peaks</h3> <p><em>(Stocks hitting 52-week highs on Aug. 13)</em></p> <ul> <li><strong>Iradimed Corp </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>)</li> <li><strong>SurModics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srdx#NASDAQ">SRDX</a>)</li> </ul> <h3>Down In The Dumps</h3> <p><em>(Stocks hitting 52-week lows on Aug. 13)</em></p> <ul> <li><strong>Acasti Pharma </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>)</li> <li><strong>Achaogen Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akao#NASDAQ">AKAO</a>)</li> <li><strong>Agile Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agrx#NASDAQ">AGRX</a>)</li> <li><strong>Arsanis Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asns#NASDAQ">ASNS</a>)(reported a wider-than-expected loss for its Q2)</li> <li><strong>aTyr Pharma Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/life#NASDAQ">LIFE</a>)</li> <li><strong>Aytu BioScience </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aytu#NASDAQ">AYTU</a>) (1-for-20 reverse stock split became effective)</li> <li><strong>Cleveland BioLabs, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbli#NASDAQ">CBLI</a>)</li> <li><strong>DelMar Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dmpi#NASDAQ">DMPI</a>)</li> <li><strong>IntelliPharmaCeutics Intl Inc (USA) </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipci#NASDAQ">IPCI</a>)</li> <li><strong>Osiris Therapeutics, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/osir#NASDAQ">OSIR</a>)</li> <li><strong>Portola Pharmaceuticals </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptla#NASDAQ">PTLA</a>)</li> <li><strong>Puma Biotechnology Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbyi#NASDAQ">PBYI</a>)</li> <li><strong>Surface Oncology Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/surf#NASDAQ">SURF</a>)</li> <li><strong>Synlogic Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sybx#NASDAQ">SYBX</a>)</li> <li><strong>Titan Medical Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdi#NASDAQ">TMDI</a>)(reacted to the announcement of Q2 results)</li> <li><strong>VBI Vaccines Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vbiv#NASDAQ">VBIV</a>)</li> </ul> <h3>Stocks In Focus</h3> <p><strong>Stocks Reacting To Earnings </strong></p> <p><strong>VolitionRX Ltd </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vnrx#NYSE">VNRX</a>) reported a loss of 15 cents per share for the second quarter, wider than the loss of 13 cents per share last year. Analysts, on average, estimated a loss of 14 cents per share. ...</p><p><a href=https://www.benzinga.com/general/biotech/18/08/12197141/the-daily-biotech-pulse-cesca-acer-therapeutics-rally-on-earnings-ari alt=The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut>Full story available on Benzinga.com</a></p> ACER ACST AGRX AIPT AKAO ARPO ARRY ASNS ATNX AYTU BASI BIOC Biotech CBLI CGIX CYTX DMPI Earnings EYEN IPCI IRMD KOOL LIFE NDRA News ONTX OPTN OSIR PBYI PTLA RSLS RXII SRDX STIM SURF SYBX TMDI URGN VBIV VNRX Top Stories Trading Ideas ARRY US04269X1054 BASI US09058M1036 CBLI US1858601032 CYTX US23283K1051 KOOL US8836233085 LIFE US53217V1098 OSIR US68827R1086 RXII SRDX US8688731004 IPCI CA4581731011 VNRX SURF PBYI CGIX PTLA ONTX BIOC US09071B1008 ACST AKAO AGRX IRMD DMPI STIM VBIV AYTU URGN ATNX NDRA ARPO SYBX ACER OPTN RSLS ASNS EYEN AIPT TMDI News Earnings Biotech Top Stories Trading Ideas Benzinga Tue, 14 Aug 2018 12:23:00 +0000 Shanthi Rexaline 12197141 at https://www.benzinga.com Savings Vs. Stocks: How Much Money Millennials Lose By Not Investing https://www.benzinga.com/general/education/18/08/12139513/savings-vs-stocks-how-much-money-millennials-lose-by-not-investing <p>A recent study <a href="https://www.bankrate.com/investing/financial-security-july-2018/">from Bankrate</a> revealed that cash is millennials&#39; preferred&nbsp;long-term investment. While cash is certainly the safest bet in the near-term, historical evidence suggests millennials who stick to this investment strategy over time will be missing out on some major wealth.</p> <h3>By The Numbers</h3> <p>According to Bankrate, 30 percent of millennials prefer cash as their favorite long-term investment. The same survey found that more than half (56 percent) of Americans with savings are earning less than 1.5 percent in annual interest on that cash.</p> <p><img alt="" src="https://cdn1.benzinga.com/files/u81483/bankrate.png" style="height:300px; width:480px" /><br /> <em>Infographic courtesy of Bankrate.&nbsp;</em></p> <p>A <a href="https://www.benzinga.com/investing/best-online-stock-broker-for-beginners/">25-year-old who invests</a> $5,000 at a 1.5-percent compound interest rate for 30 years will grow that money to $7,815&nbsp;by the time they reach age 55.</p> <p>Over the past 90 years, the average annualized return of the S&amp;P 500 index has been 9.6 percent. Using that compounded 9.6-percent return rate, $5,000 invested in stocks would grow to $78,214&nbsp;over a period of 30 years, producing total wealth roughly 10 times what a cash hoarder would accumulate.&nbsp;</p> <p>To reiterate:&nbsp;investing in cash would grow $5,000 to $7,800. Investing in stocks would grow $5,000 to $78,200.</p> <p>Unfortunately, a 1.5-percent interest rate doesn&rsquo;t even keep millennial investors in-line with the 2.9-percent inflation the U.S. reported in the most recent quarter. ...</p><p><a href=https://www.benzinga.com/general/education/18/08/12139513/savings-vs-stocks-how-much-money-millennials-lose-by-not-investing alt=Savings Vs. Stocks: How Much Money Millennials Lose By Not Investing>Full story available on Benzinga.com</a></p> Bankrate Investing millennials SPX SPY Education Crowdsourcing Top Stories Personal Finance General SPY US78462F1030 SPX Education Crowdsourcing Top Stories Personal Finance General Benzinga Mon, 13 Aug 2018 20:31:04 +0000 Wayne Duggan 12139513 at https://www.benzinga.com The Tiger Woods 'Halo Effect' Drives Up PGA Championship Ratings https://www.benzinga.com/news/18/08/12193764/the-tiger-woods-halo-effect-drives-up-pga-championship-ratings <p>If there were any lingering doubts about Tiger Woods&#39; popularity, they weren&rsquo;t evident at the PGA Championship Sunday in St. Louis.</p> <p>The golfing legend may not have won, but he stole the show and virtually of all thunder from eventual winner Brooks Koepka.</p> <p>The Tiger Woods <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11492321/tiger-woods-still-has-halo-effect-on-tv-ratings">&#39;halo effect&#39; </a>lives on. TV ratings <a href="https://deadline.com/2018/08/tiger-woods-pga-championship-ratings-cbs-1202444522/">were up 69 percent </a>from last year&#39;s PGA Championship. The event, broadcast on <strong>CBS Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cbs#NYSE">CBS</a>) saw its highest ratings since 2009, when Woods lost his chance for a 15th major to unknown Y.E. Yang.</p> <blockquote class="twitter-tweet"><p>Seven of the nine highest <a href="https://twitter.com/hashtag/PGAChampionship?src=hash&amp;ref_src=twsrc%5Etfw">#PGAChampionship</a> overnight ratings since at least 1996 have come in years when Woods won or finished second. <a href="https://t.co/rc30GzpcSC">pic.twitter.com/rc30GzpcSC</a></p> <p>&mdash; Sports Media Watch (@paulsen_smw) <a href="https://twitter.com/paulsen_smw/status/1029025141236424705?ref_src=twsrc%5Etfw">August 13, 2018</a></p></blockquote> <h3>&#39;It&#39;s Like The Old Days&#39;</h3> <p>&ldquo;Yesterday, Tiger had his patented Tiger charge and there was a huge spike in ratings. Despite ...</p><p><a href=https://www.benzinga.com/news/18/08/12193764/the-tiger-woods-halo-effect-drives-up-pga-championship-ratings alt=The Tiger Woods &#039;Halo Effect&#039; Drives Up PGA Championship Ratings>Full story available on Benzinga.com</a></p> Brad Adgate Brooks Koepka CBS CBS Sports Fox FOXA Golf News Tiger Woods Sports Top Stories Exclusives Media Interview General CBS US1248572026 FOXA US90130A1016 News Sports Top Stories Exclusives Media Interview General Benzinga Mon, 13 Aug 2018 19:30:17 +0000 Brett Hershman 12193764 at https://www.benzinga.com Analyst Says Things Could Get Worse For Deutsche Bank's Stock https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12193880/analyst-says-things-could-get-worse-for-deutsche-banks- <p><strong>Deutsche Bank AG (USA) </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/db#NYSE">DB</a>) stock is down nearly 40 percent year-to-date, but one analyst says things are going to get much worse for Deutsche Bank investors before they get better.</p> <h3>The Analyst</h3> <p>Bank of America analysts led by Andrew Stimpson downgraded Deutsche Bank from Neutral to Underperform and lowered his price target&nbsp;from 11 EUR ($12.54) to 9 EUR ($10.42).</p> <h3>The Thesis</h3> <p>There are simply too many headwinds for Deutsche Bank to overcome at the moment, Stimpson said in the note.</p> <p>First, Stimpson said Deutsche Bank&rsquo;s deleveraging process will hinder its revenue growth. He also said the bank will need more aggressive ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12193880/analyst-says-things-could-get-worse-for-deutsche-banks- alt=Analyst Says Things Could Get Worse For Deutsche Bank&#039;s Stock>Full story available on Benzinga.com</a></p> Analyst Color Andrew Stimpson Bank of America DB Downgrades Price Target Top Stories Analyst Ratings DB DE0005140008 Analyst Color Downgrades Price Target Top Stories Analyst Ratings Benzinga Mon, 13 Aug 2018 18:41:17 +0000 Wayne Duggan 12193880 at https://www.benzinga.com Goldman Drops Alnylam From Conviction List, But Continues To See 'Blockbuster Potential' https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12193114/goldman-drops-alnylam-from-conviction-list-but-continue <p>The FDA recently <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616518.htm"> approved </a> <strong> Alnylam Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>)&#39;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11052327/chardan-increases-price-target-on-alnylam-from-124-to-1"> patisiran </a> for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.</p> <p>The genetic, often lethal, disease leads to abnormal buildup of amyloid protein in peripheral nerves, heart and other organs, which results in nerve as well as organ damage.</p> <h3>The Analyst</h3> <p>Goldman Sachs analyst <a href="https://www.tipranks.com/analysts/terence-flynn">Terence Flynn</a> maintained a&nbsp;Buy rating on Alnylam and lowered the&nbsp;price target from $193 to $155.</p> <p>The analyst removed Alnylam from Goldman&#39;s Americas Conviction List.</p> <h3>The Thesis</h3> <p>The approval was in line with expectations, especially after the Eeuropean Union&nbsp;issued a positive Committee for Medicinal Products for Human Use&nbsp;opinion last month, Flynn said in a Monday&nbsp;note. (See the analyst&#39;s track ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12193114/goldman-drops-alnylam-from-conviction-list-but-continue alt=Goldman Drops Alnylam From Conviction List, But Continues To See &#039;Blockbuster Potential&#039;>Full story available on Benzinga.com</a></p> ALNY Analyst Color Biotech Goldman Sachs PFE Terence Flynn Price Target Reiteration Top Stories Analyst Ratings General ALNY US02043Q1076 PFE US7170811035 Analyst Color Biotech Price Target Reiteration Top Stories Analyst Ratings General Benzinga Mon, 13 Aug 2018 18:14:14 +0000 Shanthi Rexaline 12193114 at https://www.benzinga.com